Search results
In addition, rituximab was recently found to be efficacious in recalcitrant cases of BSLE that do not respond to dapsone and immunosuppressants. We review the topic of BSLE with emphasis on clinical, histologic, and immunopathologic features, as well as new methods of diagnosis and treatment.
Bullous systemic lupus erythematosus (BSLE) is an uncommon blistering eruption that can occur in patients with systemic lupus erythematosus (SLE). Between 59 and. 85 % of SLE patients will have skin manifestations of their disease, but less than 5 % will develop bullous disease [1–3].
26 paź 2023 · A core tenet of drug treatment for systemic lupus erythematosus is that treatment with an antimalarial (usually hydroxychloroquine) is recommended for all patients unless contraindicated.
31 paź 2014 · Clinically similar to bullous pemphigoid (BP), linear IgA bullous dermatosis, epidermolysis bullosa acquisita (EBA), and dermatitis herpetiformis (DH), it is important for physicians to consider BSLE when confronted with a bullous skin eruption.
22 maj 2023 · This activity reviews the evaluation and management of bullous systemic lupus erythematosus and highlights the role of the interprofessional team in improving care for patients with this condition. Objectives: Outline the typical presentation of a patient with bullous systemic lupus erythematosus.
25 lut 2019 · Bullous systemic lupus erythematosus: a review and update to diagnosis and treatment. Am J Clin Dermatol. 2014; 15 (6):517-24. 10.1007/s40257-014-0098-0. [Google Scholar]
31 maj 2024 · This study reported a case of bullous lupus following treatment with NB-UVB, showing significant improvement with dapsone tablet therapy. Consequently, it is advisable to consider this diagnosis for blistering lesions post-UVB treatment in patients.
